Tamar Pilishvili

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. ncbi Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
    Tamara Pilishvili
    Division of Bacterial Diseases and Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 201:32-41. 2010
  2. ncbi Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use
    Tamar Pilishvili
    Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Pediatrics 126:e9-17. 2010
  3. ncbi Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
    Cynthia G Whitney
    Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Lancet 368:1495-502. 2006
  4. ncbi Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003
    Carolyn M Greene
    Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 43:141-50. 2006
  5. ncbi Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies
    Sandra Romero-Steiner
    Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Diagn Lab Immunol 10:246-51. 2003

Collaborators

Detail Information

Publications5

  1. ncbi Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
    Tamara Pilishvili
    Division of Bacterial Diseases and Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 201:32-41. 2010
    ..Changes in invasive pneumococcal disease (IPD) incidence were evaluated after 7 years of 7-valent pneumococcal conjugate vaccine (PCV7) use in US children...
  2. ncbi Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use
    Tamar Pilishvili
    Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Pediatrics 126:e9-17. 2010
    ..We conducted a case-control study to evaluate risk factors for invasive pneumococcal disease (IPD) among children who were aged 3 to 59 months in the era of pneumococcal conjugate vaccine (PCV7)...
  3. ncbi Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
    Cynthia G Whitney
    Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Lancet 368:1495-502. 2006
    ..Our aim was to assess the effectiveness of the vaccine against various pneumococcal serotypes, and to measure the effectiveness of the recommended dose schedule and of catch-up and incomplete schedules...
  4. ncbi Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003
    Carolyn M Greene
    Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 43:141-50. 2006
    ..Our objectives were to determine the proportion of IPD cases that might have been prevented if all persons with vaccine indications had been vaccinated and to evaluate new indications...
  5. ncbi Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies
    Sandra Romero-Steiner
    Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Diagn Lab Immunol 10:246-51. 2003
    ..5 micro g/ml. Our data support the argument that PsaA is an adhesin that mediates Pnc adherence to human nasopharyngeal cells. This functional assay may be useful in evaluating antibodies elicited in response to PsaA vaccination...